fda compounding glp-1 enforcement news today 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA steps up crackdown on

The American Journal of Geriatric Psychiatry , 32 (1), 117127

CVD prevalence has more than doubled during the last three decades, with the burden of CVD borne disproportionately by individuals with diabetes, who experience a two- to four-fold higher risk of cardiovascular events and mortality [1,2,3]

Discussing test results with your PlexusDx-partnered provider helps translate genetic data into practical dose and formulation recommendations tailored to your risk profile

Additionally, lymphocyte proliferation was elevated up to 60% after 2 weeks [1]

doi: 10.1096/fasebj.14.3.543 233

Short-term stability studies highlighted formulation-dependent degradation behavior, with higher impurity formation observed for solubilized EXE-HIP than for suspended EXE acetate, particularly at room temperature